Watch first author Rona Yaeger discuss her research article, Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated #Metastatic #ColorectalCancer , published simultaneously at #AACR24 :
vimeo.com/932606282/f27a…
Memorial Sloan Kettering Cancer Center

RMC-6236 achieved the impossible. A COMPLETE RESPONSE in a heavily pretreated PDAC patient w liver and peritoneal mets Cancer Discovery
Excited lab members Grace Goodhart Amber Amparo could contribute to the nature papers leading up to this
KenOliveLab Syed A. Ahmad KRASKickers

Out NOW in Cancer Discovery!!! Don’t miss this new paper evaluating RMC-6246 in RAS-driven cancers that was just covered during #AACR24 . The data is so exciting and Ras-nerds will love it!

Be sure to read this Cancer Discovery paper by Andreana N. Holowatyj 🇺🇦 and colleauges if you want more regarding early-onset cancers after the #AACR24 session on the topic doi.org/10.1158/2159-8…

I'm feeling very happy (and proud) for all of this! Rona Yaeger

#1/8 Multicenter P1/2 trial of a personalized neoantigen vaccine + anti-PD1 (pembro) in 2L #HCC presented at #AACR2024 & published in Nature Medicine
➡️nature.com/articles/s4159…
ORR 31%,⏫historical control of pembro monotherapy (~17%)
Details below:

Il prossimo thread lo potrete ascoltare stasera a Che Tempo Che Fa.

10 women in STEM- pick it up and keep it moving!
'European heritage' edition :)
AmbrogioLab
Ralitsa Madsen
Elsa Anagnostou
mariangela russo
Eneda Toska Lab
Sabrina Arena
Amaia Arruabarrena-Aristorena
Direna Alonso-Curbelo
Anna Obenauf
Flavia Michelini

Please RT. Interested in understanding the role of chromosome instability and micronuclei in cancer development? We have a postdoc position IEO generously funded by Worldwide Cancer Research to work on this exciting topic. Starting date April 1, 2024.

Proud to be among the 12 early-career investigators selected by Nature Cancer for“The 2023 Generation Viewpoint”, a nice perspective on challenges and opportunities about being a new PI. Please read and share! rdcu.be/dtIHR
Johns Hopkins Medicine Johns Hopkins Kimmel Cancer Center KRASKickers

Don’t miss “Cancer in 2023” in Cancer Discovery, an excerpt from the AACR #CancerProgressReport 👇🏻

Don't miss Rona Yaeger editorial on NEJM !

Paolo is an amazing oncolgist and a bright physician scientist. Today, we celebrate his achievements! More to come 😉 Orgoglio Italiano (Napoletano!) Bravissimo Dr. Tarantino! Paolo Tarantino AIOM

Proud to share our work today at the AIOM National Congress together with the amazing Italian oncology community!
Fiera di condividere i nostri lavori al congresso nazionale AIOM. La comunita' oncologica italiana e' impressionante, sono fiera di essere qui! AIOM Saverio Cinieri

Out now in Clinical Cancer Research from Drs. Joseph Murray Lavanya Sivapalan & Elsa Anagnostou ! Tracking response to immunotherapy is increasingly a reality - aacrjournals.org/clincancerres/…

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C | NEJM nejm.org/doi/full/10.10…

Presidential ESMO session today by Dr. Pietrantonio! CodeBreaK 300 Phase 3 trial provides Level One Evidence for Soto + Pmab in KRAS G12C in refractory MCRC.

A lot of KRAS talks happening today at #ESMO23 ! Don't miss this@CD_AACRpaper related to these sessions: Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer by Sandra Misale et al doi.org/10.1158/2159-8…

We’re pleased to share that adagrasib + #EGFR inhibitor (cetuximab or panitumumab) has been added to the National Comprehensive Cancer Network (NCCN)'s Guidelines for Colon and Rectal cancers. #coloncancer #rectalcancer View the updated guidelines: bitly.ws/VPK2

🤩

Look at this nice group of #KRASkickers ! It's always a privilege to see you Terri ❤️ We'll keep 🚫KRASholes together! KRASKickers Andrew Waters Channing Der